CG Oncology, Inc. (CGON)
CG Oncology, Inc. (CGON)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Accounts receivable - other | NaN | NaN | NaN | -219 |
| Net loss | -60,202 | -41,309 | -43,808 | -75,878 |
| Depreciation and amortization | 841 | 849 | 416 | 180 |
| Stock-based compensation expense | 6,474 | 7,187 | 7,331 | 12,158 |
| Accretion of discount on short-term investments | NaN | -951 | -201 | 2,166 |
| Unrealized losses (gains) on short-term investments | -1,664 | NaN | NaN | NaN |
| Non-cash interest expense (income) | -46 | -76 | 169 | 675 |
| Non-cash lease expense | 13 | 13 | 8 | 13 |
| Prepaid expenses and other current assets | 8,066 | 1,810 | 105 | -15 |
| Accounts receivable, net | 587 | 301 | 19 | NaN |
| Inventory | -72 | 64 | 380 | NaN |
| Other assets | 998 | 1,564 | 7 | 13 |
| Accounts payable | 2,522 | -3,479 | 1,227 | 608 |
| Accrued expenses and other current liabilities | 1,607 | 3,731 | -3,379 | 8,303 |
| Other liabilities | -329 | -496 | 9 | NaN |
| Net cash used in operating activities | -56,943 | -36,216 | -38,894 | -57,236 |
| Proceeds from sales and maturities of investments | 252,853 | 222,240 | 621,899 | NaN |
| Proceeds from sales and maturities of short-term investments | NaN | NaN | NaN | 370,520 |
| Purchases of investments | 587,394 | 297,738 | 770,122 | NaN |
| Purchases of short-term investments | NaN | NaN | NaN | 529,852 |
| Acquisition, net of cash acquired | NaN | 0 | 21,967 | NaN |
| Purchases of property and equipment | 304 | 7 | 97 | 30 |
| Issuance of note receivable | NaN | NaN | NaN | 26,000 |
| Net cash used in investing activities | -334,845 | -75,505 | 15,045 | -185,362 |
| Proceeds from follow-on public offerings, net of issuance costs | 391,550 | 98,449 | 49,001 | NaN |
| Proceeds from exercise of common stock options | 1,669 | 656 | 5,099 | 701 |
| Withholding taxes paid on net exercise of stock options | 174 | NaN | NaN | NaN |
| Deferred offering costs | NaN | NaN | 270 | -547 |
| Stock issuance costs | 47 | 316 | NaN | NaN |
| Net cash provided by financing activities | 392,998 | 99,066 | 54,370 | 154 |
| Net increase (decrease) in cash and cash equivalents | 1,210 | -12,655 | 30,521 | -242,444 |
| Cash and cash equivalents at beginning of period | 32,490 | 45,145 | 257,068 | NaN |
| Cash and cash equivalents at end of period | 33,700 | 32,490 | 45,145 | NaN |